Goldman's $120 Brent call is the day's least-priced risk.

Transcript

Tom Oil at one-twenty? That's the day's least-priced risk, and it's sitting right under the market's nose.

Marie Good morning — Tuesday, July twenty-first, New York edition. I'm Marie, with Tom and Gerald. And Gerald, last session's moves open with a real stunner.

Gerald Yeah look, Goldman dropping a one-twenty Brent call is not window dressing. That's a tail risk the market has been half-pricing at best.

Tom Half-pricing? Buddy, USO is up eighty-two percent year to date. It's at the ninetieth percentile of its fifty-two-week range. The premium is already in there.

Marie Tom, wait — that's exactly why I'm going to push back. If a closure event happens, you get outsized upside. But the whole thing is a conditional trade on the Strait of Hormuz staying shut.

Gerald Right, and the flip side is ceasefire chatter. We saw Asian equities move on it last session. One headline and USO unwinds ten percent. This is a crowded theater.

Tom Crowded, sure. But Goldman's not calling it for nothing — petrol's already above four dollars, and midterms are coming. That's real political pressure keeping the bid alive.

Marie Honestly, I'm more interested in what oil does to the C P I print on Friday. Four-dollar gas isn't just a consumer tax, it's a Fed problem. And bonds — TLT at a fifty-two-week low — haven't priced in a hawkish repricing.

Gerald Spot on. That's the signal nobody's talking about. The energy trade has momentum, but the real pain could be in duration if inflation stays sticky.

Tom Alright, so we're all long energy and short bonds? Because that pair trade is printing.

Gerald Ha — Tom, I thought you'd never ask. But let's talk AI first, because that's where the pain is hitting hardest.

Marie Yeah, and Gerald, your perma-bear on semis is aging well. Fairlead's Katie Stockton says the bounce is unsustainable — technicals point to more downside.

Gerald To be fair, SOXX is down seven point seven percent in a week. A relief rally on low conviction is a sell signal, not a buy. And the WSJ piece today — 'Something Weird Is Happening Beneath the Surface' — that's code for internal divergence.

Tom Gerald, come on. The Nasdaq's down only three point three percent over the week. AI fundamentals aren't broken. Microsoft trades at twenty point eight times forward after a fifteen percent year-to-date drop. This is a dip, not a crack.

Marie Tom — Tom, that's the THIRD time this month you've called the bottom on semis. The rotation into energy and defensives is real. Look at the breadth indicators.

Gerald And the divergence the WSJ is flagging — narrow leadership masking weakness — that's classic late-cycle. I'm with Stockton: reduce exposure.

Tom Alright, fair. But if we get a dovish turn on rates, AI comes roaring back. Microsoft at these multiples is cheap for the capex they're doing.

Marie Which brings us to the FT's piece on Big Tech backstops. Microsoft and Alphabet are effectively lending their balance sheets to unproven AI startups. That's contingent tail risk if the AI hype fades.

Gerald Honestly, it's an 'ignominy' risk — the FT's word. Alphabet's up twelve percent year to date, Microsoft's down fifteen. Neither price reflects the hidden credit exposure.

Tom But that's the whole AI bull case — these companies win either way. If startups fail, they absorb the IP. It's not like Enron off-balance-sheet stuff. It's strategic.

Marie Strategic or not, it's a liability. And in a downturn, those liabilities get marked. I'm putting both on watch.

Gerald Speaking of liabilities, did you see the biotech deal surge? Record mergers and acquisitions, and an eight-hundred-million-dollar fund for AI drug discovery — even though no AI-discovered drug is approved yet.

Tom Gerald, that's the opportunity! Recursion Pharma is down thirty-one percent year to date, near its fifty-two-week low. If sentiment shifts, that's a catch-up trade waiting to happen.

Gerald Yeah, but the fund raise is venture capital, not public markets. And XBI is already up twenty-four percent year to date — that's mergers and acquisitions premium, not fundamentals.

Marie Hold on — Pfizer is flat year to date, and they're a likely acquirer. But deal costs could weigh. I'd hold Pfizer, but the pure-play biotech ETF is a buy on momentum.

Tom Exactly. And the India story adds to the risk-on case. SBI Funds' billion-dollar I P O surged eight and a half percent on debut. Three sources confirm: it's the biggest subscription this year.

Gerald Alriiiight, but INDA is still down eleven percent year to date, only seven percent above its low. One I P O doesn't fix macro uncertainty in emerging markets.

Marie But sentiment catalysts matter, Gerald. This could be the spark for a re-rate. I'm with Tom — buy the India ETF.

Gerald Fair enough. Though if we're talking emerging markets, Moody's warning on Indonesia is flashing red. Policy uncertainty, fiscal risks — EIDO is down thirty-three percent year to date. That trend is not your friend.

Tom Thirty-three percent down? Buddy, that's a falling knife. I'm not catching that.

Marie No — stay away. And while we're on sell signals, did you catch the Australia bank disruption? Revolut got a full banking licence and plans to target the Big Four.

Gerald Look mate, Commonwealth Bank at twenty-five times forward P-E with a new fintech challenger? That's a re-rating waiting to happen. Westpac at seventeen times is also exposed. Both are sells.

Tom Disruption plays are tough because incumbents have scale. But with Revolut's brand, I'd short the Aussie banks too.

Marie And back home, Jamie Dimon warning a UK bank tax under Burnham would have 'consequences'. Lloyds, as a domestic play, is at nine point three times forward but right in the crosshairs.

Gerald JP Morgan is globally diversified, so hold. But Lloyds — up thirteen percent year to date, yet the tax headwind isn't priced. Sell Lloyds.

Tom Alright, selling banks across the globe — a true Gerald special. But hey, remember yesterday's buy call on Domino's? That was a win.

Gerald Ha — fair enough. And your Hut 8 call is up today. So maybe I'll give you semis another day.

Marie Let's not get too cozy. The media mergers and acquisitions pause is a risk. A judge froze Paramount's one-hundred-ten-billion-dollar Warner Bros Discovery deal — antitrust concerns. WBD fell three point eight percent last session.

Tom If the deal collapses, WBD, down nine percent year to date, has further to fall. That premium unwinds hard.

Gerald Sell WBD. And on the macro side, Asia ex-Japan equities jumped on ceasefire hopes — AAXJ up point four percent last session. But it's still down three point two percent for the week.

Marie Ceasefire hopes are fragile. If Iran talks collapse, the oil bid returns and Asia gets hit. I'd buy AAXJ only as a short-term trade.

Tom Yeah, but it's up fifteen percent year to date. Momentum may carry it if the Middle East cools. Meanwhile, Japan's in a tug-of-war — ceasefire hopes versus rising JGB yields. EWJ flat last session, down three point seven percent for the week.

Gerald The JGB selloff is tracking Treasuries, and that yield pressure is a valuation headwind. I'm watching Japan — direction unclear until we see which force wins.

Marie And on the Treasury side, TLT is at a fifty-two-week low, down three point six percent year to date. The inverse correlation with oil is the story — sell long duration until oil peaks.

Tom So to sum up: energy over AI, short bonds, and selective equities. That's the rotation.

Gerald The cleanest expression: long energy stocks, XLE, versus short semis, SOXX. Energy has momentum and geopolitical tailwind; semis have technical damage and crowded positioning.

Marie One hundred percent. And that trade doesn't bet on a single outcome — it captures the rotation regardless of ceasefire or oil spike.

Tom And as always, none of this is investment advice — just our pre-market read. If you're just finding us, hit follow on Spotify or check investmentflash.com for the full digest with charts and sources.

Marie We're back at seven-thirty a.m. London time tomorrow. See you then.